Please ensure Javascript is enabled for purposes of website accessibility

Why Diabetes Stock Insulet Soared 25% in August

By Beth McKenna – Sep 4, 2019 at 8:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The market has been pumped up about shares of the leader in tubeless insulin pump technology, which have more than doubled in 2019.

What happened

Shares of Insulet (PODD 4.85%) rocketed 25.4% higher in August, according to data from S&P Global Market Intelligence. The stock has pumped out a gain of 108% in 2019 through Sept. 3, making it one of the year's best-performing medical device stocks within the broader healthcare arena

The Boston-area company is the leader in tubeless insulin pump technology with its Omnipod pump.

Insulet stock's August performance is even more impressive when you consider that the market had a down month. The S&P 500, including dividends, fell 1.6% last month, and has returned 17.5% so far this year.

A two-pane image with the top pane showing an Omnipod attached to a woman's lower stomach and the bottom pane showing the handheld control for the device.

Image source: Getty Images.

So what

We can attribute Insulet stock's strong performance last month to the company's Aug. 5 release of its second-quarter results, which were better than Wall Street and many investors were expecting, and to management once again increasing full-year 2019 revenue guidance. Shares surged 21.4% on the day following the release and continued to move somewhat higher throughout the remainder of the month.

In Q2, Insulet's revenue soared 43% year over year to $177.1 million, easily beating the $164 million Wall Street was looking for. Earnings per share came in at $0.02 -- versus a loss of $0.03 per share in the year-ago period -- hitting the consensus estimate on the bull's-eye. 

Now what

For the third quarter, Insulet guided for revenue growth of about 15% to 20% year over year. And for full-year 2019, it expects revenue to increase about 24% to 27%, up solidly from its previous outlook of 18% to 22% growth. The company doesn't provide earnings guidance.

Beth McKenna has no position in any of the stocks mentioned. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Insulet Corporation Stock Quote
Insulet Corporation
$244.27 (4.85%) $11.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.